{"id":99713,"date":"2014-01-10T10:51:10","date_gmt":"2014-01-10T15:51:10","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/uc-san-francisco-and-quest-diagnostics-launch-collaboration-to-advance-the-field-of-precision-medicine.php"},"modified":"2014-01-10T10:51:10","modified_gmt":"2014-01-10T15:51:10","slug":"uc-san-francisco-and-quest-diagnostics-launch-collaboration-to-advance-the-field-of-precision-medicine","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/uc-san-francisco-and-quest-diagnostics-launch-collaboration-to-advance-the-field-of-precision-medicine.php","title":{"rendered":"UC San Francisco and Quest Diagnostics launch collaboration to advance the field of precision medicine"},"content":{"rendered":"<p><p>    PUBLIC RELEASE DATE:  <\/p>\n<p>    9-Jan-2014  <\/p>\n<p>    Contact: Kristen Bole    <a href=\"mailto:kristen.bole@ucsf.edu\">kristen.bole@ucsf.edu<\/a>    415-502-6397    University of California - San    Francisco<\/p>\n<p>    MADISON, N.J. and SAN FRANCISCO, CA, January 9, 2014  Quest    Diagnostics (NYSE: DGX), the world's leading provider of    diagnostic information services, and the University of    California, San Francisco (UCSF), the nation's leading    university focused exclusively on health, have formed a    collaboration to accelerate the translation of biomedical    research into advanced diagnostics in the field of precision    medicine, for improved patient care, treatment and outcomes.    Initial clinical areas of focus include autism, oncology,    neurology and women's health.  <\/p>\n<p>    The collaboration, which combines the research discoveries and    capabilities of UCSF with the national testing database and    technical and clinical development capability of Quest    Diagnostics, has an overarching aim of enabling holistic and    integrated diagnostic solutions that close gaps in care or    enable new clinical value.  <\/p>\n<p>    Under the terms of the agreement, scientists will jointly    research, develop and validate diagnostic innovations to solve    specific clinical problems and provide actionable information    to improve patient care. The organizations will focus on    diagnostics to advance precision medicine, an emerging field of    medical science that aims to integrate the most informative    data from molecular, clinical, population and other research to    create predictive, preventive and precise medical solutions for    patients. Quest Diagnostics would independently develop and    validate any lab-developed tests for clinical use that emerge    from the collaboration's research.  <\/p>\n<p>    Researchers will utilize laboratory-based diagnostics, imaging    procedures and population analysis based on Quest's national    Health Trends database, the largest private clinical database    in the U.S., based on more than 1.5 billion patient encounters,    to advance precision medicine.  <\/p>\n<p>    The alliance is the first master agreement that UCSF's Office    of Innovation, Technology and Alliances has signed with a    clinical laboratory testing company and augments the    university's efforts to translate laboratory research into new    therapies. The broad agreement lays the groundwork for multiple    projects between the two organizations.  <\/p>\n<p>    \"Advances in technology and science have identified many    promising opportunities to improve outcomes through insights    revealed by novel diagnostic solutions, yet fulfilling the full    potential of these opportunities often hinges on translational    clinical studies which validate their value,\" said Jay    Wohlgemuth, M.D., senior vice president, Science and    Innovation, Quest Diagnostics. \"This unique collaboration    between UCSF and Quest brings together the finest researchers    and clinicians in the country to accelerate the development of    a 'product pipeline' of scientific discoveries as clinically    valuable diagnostic solutions that enable precision medicine    for improved outcomes.\"  <\/p>\n<p>    The collaboration is launching with two specific projects    already underway. One project involves Quest's national    database of molecular testing data to facilitate participation    in research and development efforts related to genetic    variations of autism, based on Quest's CGH microarray    ClariSure technology, which can help identify genetic    mutations associated with autism and other developmental    disorders. While there currently is no treatment for autism, a    test that aids its diagnosis could help identify individuals    who might be appropriate candidates for research studies that    could lead to future therapies.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>More:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2014-01\/uoc--usf010914.php\" title=\"UC San Francisco and Quest Diagnostics launch collaboration to advance the field of precision medicine\">UC San Francisco and Quest Diagnostics launch collaboration to advance the field of precision medicine<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> PUBLIC RELEASE DATE: 9-Jan-2014 Contact: Kristen Bole <a href=\"mailto:kristen.bole@ucsf.edu\">kristen.bole@ucsf.edu<\/a> 415-502-6397 University of California - San Francisco MADISON, N.J. and SAN FRANCISCO, CA, January 9, 2014 Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and the University of California, San Francisco (UCSF), the nation's leading university focused exclusively on health, have formed a collaboration to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine, for improved patient care, treatment and outcomes <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/molecular-medicine\/uc-san-francisco-and-quest-diagnostics-launch-collaboration-to-advance-the-field-of-precision-medicine.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[26],"tags":[],"class_list":["post-99713","post","type-post","status-publish","format-standard","hentry","category-molecular-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/99713"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=99713"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/99713\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=99713"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=99713"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=99713"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}